药物发现和开发的基本原则 1336条(本栏目收费,不能显示细节,电话13136136841)
green fluorescent protein (GFP),170–171 171
membrane potentials and ion channels, 169–170 170
yellow fluorescent protein (YFP),170–171 171
Time-resolved fluorescence resonance 0
energy transfer (TRFRET) 0
Allophycocyanin, 173–174 174
background fluorescence, 172–173,173f 173
downstream cellular activity, 174–175,174f 174
GPCR signaling pathway, 174–175 175
kinase activity, 173–174, 173f 173
lanthanide-based fluorophores,172–173, 172f 172
Fluorescent Imaging Plate Reader (FLIPR),184–185 185
Food, Drug, and Cosmetic Act, 383 383
Forced swimming test, 315, 315f 315
excipients, 391–393, 392t 392
antiadherents, 391–392, 392t 392
colorants and antioxidants, 391–392 392
disintegrants, 392, 392t 392
dry binders fillers, 392t 392
glidants, 391–392, 392t 392
drug supply, 387f. See also Drug supply 387
formulation. See Formulation 0
patient randomization, 385 385
phase I, 9–10, 397–398, 398f 398
dose limiting toxicities (DLT), 397,398f 398
maximum tolerated dose (MTD),397–398, 398f 398
multiple ascending dose (MAD) study,397–398 398
NOAEL (no observed adverse effect level), 397 397
single ascending dose (SAD) study,397–398 398